Hubert Hackl - Publications

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology

Published: March 25, 2026

HTK Is a Viable UW Alternative for Hypothermic Oxygenated Machine Perfusion of Liver Grafts Supporting a Single-Solution Protocol.

Journal: Journal of clinical medicine

Published: October 31, 2025

The Role of Plasmacytoid Dendritic Cells in the Immune Contexture of TP53-Mutated High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: October 26, 2025

Deletion of MMP12 improves energy metabolism and brown adipose tissue function in mice prone to cardiometabolic disease.

Journal: Journal of lipid research

Published: August 21, 2025

Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure-A multivariable model with APRI+ALBI.

Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Published: March 03, 2025

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Journal: Nature

Published: February 25, 2025

Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations.

Journal: Leukemia

Published: February 12, 2025

Newly identified oncolytic VSV-GP-specific CD8+ T cell epitopes for monitoring of anti-viral immune responses in the BALB/c mouse model.

Journal: Molecular therapy. Oncology

Published: February 07, 2025

Myrobalan Fruit Extracts Modulate Immunobiochemical Pathways In Vitro.

Journal: Antioxidants (Basel, Switzerland)

Published: February 06, 2025

Impaired surface receptor expression on immature platelets in bleeding patients with abnormal light transmission aggregometry.

Journal: Journal of thrombosis and haemostasis : JTH

Published: February 01, 2025

Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 02, 2024

Modeling omics dose-response at the pathway level with DoseRider.

Journal: Computational and structural biotechnology journal

Published: November 29, 2024